FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Endocrine Cancer
Practice Setting Linked to Receipt of More Costly Cancer Drugs
Receiving cancer treatment at a non–National Cancer Institute-designated Comprehensive Cancer Center was associated with higher drug cost, a cohort study found.
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Does Radioactive Iodine Treatment for Hyperthyroidism Confer A Higher Cancer Risk?
Over the past decade, researchers have found inconsistent evidence about whether radioactive iodine treatment for hyperthyroidism can cause cancer in the long term.
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Next post in General Oncology
